Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97


Ability of SPI2 mutant of S. typhi to effectively induce antibody responses to the mucosal antigen enterotoxigenic E. coli heat labile toxin B subunit after oral delivery to humans.

Khan S, Chatfield S, Stratford R, Bedwell J, Bentley M, Sulsh S, Giemza R, Smith S, Bongard E, Cosgrove CA, Johnson J, Dougan G, Griffin GE, Makin J, Lewis DJ.

Vaccine. 2007 May 22;25(21):4175-82. Epub 2007 Mar 21.


Salmonella typhi and S typhimurium derivatives harbouring deletions in aromatic biosynthesis and Salmonella Pathogenicity Island-2 (SPI-2) genes as vaccines and vectors.

Khan SA, Stratford R, Wu T, Mckelvie N, Bellaby T, Hindle Z, Sinha KA, Eltze S, Mastroeni P, Pickard D, Dougan G, Chatfield SN, Brennan FR.

Vaccine. 2003 Jan 17;21(5-6):538-48.


Evaluating the A-Subunit of the Heat-Labile Toxin (LT) As an Immunogen and a Protective Antigen Against Enterotoxigenic Escherichia coli (ETEC).

Norton EB, Branco LM, Clements JD.

PLoS One. 2015 Aug 25;10(8):e0136302. doi: 10.1371/journal.pone.0136302. eCollection 2015. Erratum in: PLoS One. 2015;10(9):e0138938.


Safety and immunogenicity of bacterial and tobacco plant cell line derived recombinant native and mutant Escherichia coli heat-labile toxin in chickens.

Miller T, Fanton M, Nickelson S, Mason H, Webb S.

Avian Pathol. 2012 Oct;41(5):441-9. doi: 10.1080/03079457.2012.709606. Epub 2012 Aug 28.


Evaluation of different promoter sequences and antigen sorting signals on the immunogenicity of Bacillus subtilis vaccine vehicles.

Paccez JD, Nguyen HD, Luiz WB, Ferreira RC, Sbrogio-Almeida ME, Schuman W, Ferreira LC.

Vaccine. 2007 Jun 11;25(24):4671-80. Epub 2007 Apr 25.


Construction and evaluation of a fluorescence-based live attenuated Escherichia coli delivery system for generating oral vaccine candidate.

Liu W, Li X, Bao J, Guan W, Zhao Z, Yuan C, Tang J, Shi D.

Appl Microbiol Biotechnol. 2015 May;99(9):4005-18. doi: 10.1007/s00253-014-6332-0. Epub 2015 Jan 8.


Stable episomal expression system under control of a stress inducible promoter enhances the immunogenicity of Bacillus subtilis as a vector for antigen delivery.

Paccez JD, Luiz WB, Sbrogio-Almeida ME, Ferreira RC, Schumann W, Ferreira LC.

Vaccine. 2006 Apr 5;24(15):2935-43. Epub 2005 Dec 27.


Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant.

Holmgren J, Bourgeois L, Carlin N, Clements J, Gustafsson B, Lundgren A, Nygren E, Tobias J, Walker R, Svennerholm AM.

Vaccine. 2013 May 7;31(20):2457-64. doi: 10.1016/j.vaccine.2013.03.027. Epub 2013 Mar 27.


In vivo expression and immunoadjuvancy of a mutant of heat-labile enterotoxin of Escherichia coli in vaccine and vector strains of Vibrio cholerae.

Ryan ET, Crean TI, John M, Butterton JR, Clements JD, Calderwood SB.

Infect Immun. 1999 Apr;67(4):1694-701.


Optimization of Salmonella enterica serovar typhi DeltaaroC DeltassaV derivatives as vehicles for delivering heterologous antigens by chromosomal integration and in vivo inducible promoters.

Stratford R, McKelvie ND, Hughes NJ, Aldred E, Wiseman C, Curtis J, Bellaby T, Bentley M, Hindle Z, Brennan FR, Chatfield SN, Dougan G, Khan SA.

Infect Immun. 2005 Jan;73(1):362-8.


Comparison of the antibody in lymphocyte supernatant (ALS) and ELISPOT assays for detection of mucosal immune responses to antigens of enterotoxigenic Escherichia coli in challenged and vaccinated volunteers.

Carpenter CM, Hall ER, Randall R, McKenzie R, Cassels F, Diaz N, Thomas N, Bedford P, Darsley M, Gewert C, Howard C, Sack RB, Sack DA, Chang HS, Gomes G, Bourgeois AL.

Vaccine. 2006 May 1;24(18):3709-18. Epub 2005 Jul 26.


Supplemental Content

Support Center